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ABSTRACT
Objective: This study aimed to evaluate annual consumption during 2004-2013 of diazepam, an essential medicine which is controlled under the 
1971 Convention on Psychotropic Substances in Indonesia and to investigate factors influencing its use in health facilities.
Methods: This was a case study with quantitative and qualitative approaches. Annual consumption was calculated from the quantity of exports and 
imports. The use of diazepam was calculated from consumption deducted by 20% buffer stock. The consumption and use of diazepam were presented 
in kilogram and also in defined daily doses for statistical purposes (S-DDD). In-depth interviews were conducted to investigate factors that influence 
the use of diazepam. Triangulation was conducted to confirm the qualitative and quantitative findings.
Results: The annual average consumption in 2004-2006 was 530 kg. Furthermore, it decreased 38% during 2011-2013 to 329 kg. Calculated use of 
diazepam also decreased. The average consumption for the 10-year period of diazepam was 470 kg, and the calculated use was 376 kg (0.45 S-DDD). 
Considering the approximate need of diazepam to treat various health problems, its use should ideally be around 1-2 S-DDD. Therefore, the calculated 
use of diazepam was considered too low as confirmed by frequent stockouts. The interviews revealed that among the factors influencing its use was 
its limited production. There was an increased use of alprazolam, but it was unlikely to compensate for the diazepam stockouts.
Conclusion: Consumption and use of diazepam for medical purposes in Indonesian decreased over 10 years, and stockouts are often reported. The 
government should improve its availability and correct impediments for adequate production and supply of diazepam.
Keywords: Diazepam, Essential medicine, Consumption, Psychotropic medicine use.
INTRODUCTION
Diazepam is an essential medicine of the benzodiazepine group which 
is listed on the 19th WHO Model List of Essential Medicines 2015 [1] and 
the Indonesian List of Essential Medicines 2015 [2]. Essential medicines 
must be available at anytime in appropriate dosage to be accessed by all 
people [3]. Access for essential medicine is affected by reliable health 
and supply systems, rational use of medicine, cost affordability, and 
sustainable financing [4].
The use of diazepam is under national and international control. 
Nationally, its use is regulated by Law No. 5/1997 on Psychotropics. 
While internationally, it is regulated by the Convention on 
Psychotropic Substances of 1971. These provisions aim to assure 
the availability of psychotropics for medical and scientific purposes 
while preventing their abuse [5]. Diazepam is used as an anxiolytic, 
antiepileptic, muscle relaxant, and in induction of anesthesia [6]. 
It is often abused with alcohol, opioids, and z-drugs [7,8], but even 
so, the availability for medical and scientific purposes should be 
fulfilled.
Annual global consumption of diazepam during the period of 2004-
2006 decreased by 20% compared to 2011-2013 from 5.2 defined 
daily doses for statistical purposes (S-DDD) to 4.1 S-DDD per day 1000 
population. S-DDD, a technical unit of measurement for statistical 
analysis purposes based on prescription dose. The largest decreases 
in consumption were observed in Asia (70%) and in America (44%). 
The average consumption in Asia during 2004-2006 was 2.56 S-DDD 
and decreased to 0.76 S-DDD in the period of 2011-2013. Africa 
and Oceania meanwhile experienced decreases of 70% and 11%, 
respectively [9].
Diazepam consumption in the ASEAN region with <1 S-DDD in 2011 was 
observed in Lao PDR (0.72 S-DDD), Malaysia (0.46 S-DDD), Cambodia 
(0.33 S-DDD), Vietnam (0.24 S-DDD), and the Philippines (0.04 S-DDD). 
The high consumption rates were observed in Thailand with 4.17 S-DDD 
and Singapore with 2.11 S-DDD [10]. No previous publication was available 
regarding the consumption of diazepam in Indonesia. Therefore, this study 
will reveal this situation and the trend of its consumption pattern in the 
last 10 years. The objective of the study was to evaluate the consumption 
of diazepam in Indonesia during the 10-year period of 2004-2013 and 
to investigate factors influencing its use in health facilities. Results of this 
study will be a strong basis for improving the quality of medical care.
METHODS
This was a case study with quantitative and qualitative approaches 
which was conducted between April and June 2016. The study was 
divided into two phases. The first phase was a quantitative review 
of diazepam consumption in Indonesia during 2004-2013 through 
the data published by International Narcotics Control Board (INCB) 
and the archive of the Directorate of Pharmaceutical Production and 
Distribution, Ministry of Health of Indonesia.
Annual consumption was calculated from the quantity of imported 
diazepam (kg) reduced by the quantity to be used for the manufacturing 
of exported diazepam products. The use of diazepam was calculated 
from consumption deducted by 20% buffer stock. The consumption 
and use were presented in a kilogram. The S-DDD was calculated from 
the amount of diazepam consumed or used in the country (in mg), 
divided by the DDD of diazepam (which is 10 mg based on its medical 
use as an anxiolytic), number of days in a year (365), and the country 
population in thousand unit.
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The second phase of the study was investigating factors influencing 
the use of diazepam. In-depth interviews were conducted with 14 key 
informants consisting of two informants from the Directorate of 
Pharmaceutical Production and Distribution, Ministry of Health, one 
informant from the National Agency for Drug and Food Control, one 
informant from the National Narcotics Board, one informant from the 
National Police Criminal Investigation Directorate, two informants 
from Kimia Farma Pharmaceutical Company, one informant from 
the Provincial Office of National Agency for Drug and Food Control 
in Yogyakarta, one informant from the Provincial Health Office of 
Yogyakarta, and five informants from Pharmaceutical Wholesalers. 
Interviews were followed by text messaging for completion of the 
information. Triangulation was applied to confirm the findings.
The proposal of the study has been approved by the Ethics Committee 
of Faculty of Medicine, Universitas Gadjah Mada (KE/FK/32/EC/2016) 
on April 6th 2016. Permission to conduct the study has been obtained 
from relevant institutions. All key informants signed written informed 
consents after receiving complete information regarding the objective 
and the procedure of the study.
RESULTS
Consumption and use of diazepam
The annual average consumption of diazepam in 2004-2006 was 
530 kg, then was decreasing by 38% during 2011-2013 to 329 kg. The 
lowest consumption was in 2012 (263 kg) and the highest consumption 
was in 2008 (684 kg). In the period of 10 years (2004-2013), diazepam 
average consumption was 470 kg. Data on diazepam consumption and 
use within the period of 10 years are presented in Table 1.
Diazepam use was decreasing in the last 10 years. In 2013, its use 
was 0.37 S-DDD compared to the average of 0.45 S-DDD. Based on 
approximate need of diazepam to treat various indications (anxiolytic, 
antiepileptic, muscle relaxant, and anesthetic induction), the authors 
calculated that the use of diazepam should ideally be around 1-2 S-DDD. 
Therefore, the use of diazepam in Indonesia is considered too low. It 
means that many patients did not receive this medicine. This shortage 
was confirmed by frequent stockouts. From the interviews, informants 
stated that factors that influenced diazepam use included its limited 
availability in health facilities, and stockouts of generic diazepam, 
particularly. Below is the statement of a key informant from Provincial 
Office of Drug and Food Control.
 “Shortages in 2014 could be overcome, but in 2015 the stockouts 
occurred more frequent than before. In addition, we do not know 
about the supplier. The problem is in its factory” (Informant from the 
Provincial Office of National Agency of Drug and Food Control).
Limited availability or even stockouts of medicine led to a reduction of 
its use in health facilities. Stockouts of generic diazepam also occurred 
in supplier level. This was a quote from one key informant at Provincial 
Office of National Agency of Drug and Food Control.
 “As far as we know, there was no stock in wholesalers (because of 
no supply). It is difficult to get generic diazepam, I do not know why. 
Stockouts are getting frequent now. The only available diazepam is 
branded products” (Informant from the Provincial Office of National 
Agency of Drug and Food Control).
The difficulties of stocking generic diazepam were confirmed by five 
key informants from pharmaceutical wholesalers. They mentioned that 
only two pharmaceutical wholesalers provided generic diazepam and 
three did not provide generics. Stockouts of generic diazepam generally 
occurred in non-government wholesalers. Analysis of diazepam use in 
Yogyakarta through report from the system information of narcotics 
and psychotropic use (SIPNAP) during 2014-2016 revealed that the 
use of generic diazepam was between 8% and 17% of the overall use. 
Stockouts of generic diazepam at supplier level lead to low use of the 
medicine in public health facilities. However, while branded diazepams 
were available, the use of diazepam was considered too low.
Diazepam production
Import of diazepam quantity fluctuated during 2004-2013. It increased 
in 2010, but was always below one ton annually. Diazepam raw 
material was imported from India, Italy, China, and Denmark. Export 
of diazepam increased during 2010-2013, although it was <500 kg. 
Branded diazepams were exported to Cambodia, Hong kong, New 
Zealand, Singapore, Sri Lanka, and Taiwan. The data showed that the 
amounts of imported and exported diazepam increased, but the amount 
of diazepam used domestically tended to decrease.
The domestic use of diazepam was in generic and branded forms, 
while export was in the form of branded products. Branded diazepam 
production to fulfill export need was stated from a key informant from 
Kimia Farma Pharmaceutical Company.
 “There are needs of this branded product, stockouts are in generic 
form, but the branded form is available. The product that exported 
was the branded, not the generic. They produce it for export purpose” 
(Informant from Kimia Farma Pharmaceutical Company).
Diazepam is used in primary and secondary health facilities, in public, 
and private health sectors. The use in public facilities is preferred in 
generic form, while private use in both generic and branded. Therefore, 
production of generic diazepam should be increased. From the data 
of diazepam use reported by health facilities to the Ministry of Health 
through SIPNAP, there were 42 products of single and combination 
diazepam in generic and branded products that had to be reported 
monthly. Of these products, there were four generic and the rest were 
branded. Unfortunately, separate data on the quantity of generic and 
branded diazepams used in health facilities were unavailable.
There are 17 pharmaceutical companies that produce diazepam, three 
government-owned and 14 private pharmaceutical companies. It is 
unknown whether the company tends to produce a more branded product 
Table 1: Consumption and use of diazepam in Indonesia during 2004‑2013
Year Import (kg) Export (kg) Consumption (kg) Use (kg) Use (S‑DDD)
2004 614 0 614 491.2 0.62
2005 380 0 380 304 0.38
2006 596 0 596 476.8 0.58
2007 455 0 455 364 0.44
2008 684 0 684 547.2 0.66
2009 NA NA NA NA NA
2010* 562.540 46.234 516.306 413.045 0.48
2011* 579.103 272.489 306.614 245.291 0.28
2012* 745.530 483 262.530 210.024 0.23
2013* 914.972 497.967 417.005 333.604 0.37
Average 470.162 376.129 0.45
Sources: INCB, 2005-2015; *Indonesia Ministry of Health, 2015; NA: Data not available, DDD diazepam as anxiolytics=10 mg, DDD: Defined daily doses, 
INCB: International Narcotics Control Board
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than generic. According to two pharmacists from a pharmaceutical 
company and supervisory institution, they confirmed that generic 
diazepam was priced IDR 100, while branded diazepam was IDR 300. 
The two informants also expressed that even though the price is low, the 
administrative procedure is very tight due to regulatory control.
 “The price of generic diazepam is IDR 100. However, the risk 
(administration and supervisory) is extraordinary, same as narcotics” 
(Informant from Kimia Farma Pharmaceutical Company).
At retailers, the highest price for 2 mg generic diazepam tablet in May 
2016 was IDR 156/tablet, while the price for branded was between IDR 
1500-2000/tablet.
Diazepam versus alprazolam use
The diazepam unavailability caused decreases in diazepam use and an 
increases in the use of other substances which have the same indication, 
such as alprazolam. Four informants stated that there was an increase 
in alprazolam prescriptions. Below are quotes from key informants:
 “… many physicians prefer using alprazolam, considering its comforting 
effect on patients, alprazolam is more comfortable, but if the 
mechanism and addiction effect are taken into account, alprazolam 
is more dangerous when compared to diazepam, although they are 
both from the same benzodiazepine group” (Informant from National 
Narcotics Board).
“Trend of diazepam usage is declining, it had changed to alprazolam. I see 
that physician’s prescription is shifting toward alprazolam. Diazepam 
is rarely prescribed. Maybe that is the reason why patients in need of 
psychiatric medicine are commonly prescribed with alprazolam maybe 
that is the beginning of the decline of diazepam usage. Medical world is 
dynamic, isn’t it?” (Informant from Provincial Office of National Agency 
of Drug and Food Control).
Diazepam consumption decreased in 2010, and concurrently, 
alprazolam consumption increased. Differences in diazepam and 
alprazolam consumption are shown in Fig. 1.
The increase in alprazolam consumption indicated an increase in 
alprazolam use, although the total consumption amount of diazepam 
together with alprazolam was less than 1 S-DDD. It was unclear whether 
alprazolam use increased in public or private health-care facilities because 
alprazolam is not included in the National List of Essential Medicines and 
was not used at public primary health care level. It is possible that the 
increase occurs in private facilities or public referral health-care facilities. 
The increase in alprazolam use did not meet with diazepam demand 
because the two medicines have different places in medical treatment. 
Moreover, the total use of the two medicines was still less than 1 S-DDD.
DISCUSSION
Efforts to ensure diazepam availability for medical uses
Diazepam consumption in Indonesia was decreasing in the last 
10 years and it was always below 1 S-DDD. Out of 164 countries that 
reported to the INCB during 2011-2013, there were 37 countries that 
consumed diazepam higher than the global average where the highest 
consumption were Ghana (50.5 S-DDD), Yugoslavia (26.1 S-DDD), and 
Croatia (25.9 S-DDD). While 90 countries consumed diazepam less 
than 1 S-DDD per 1000 people per day and 22 countries consumed less 
than 0.1 S-DDD [10]. Diazepam consumption in Indonesia and several 
ASEAN countries were less than 1 S-DDD [11,12].
The Special Region of Yogyakarta is a province in the Republic of 
Indonesia, which uses the SIPNAP reporting system to provide the 
data of psychotropics use, including diazepam, monthly. From the 
SIPNAP data, it is known that there was 53% increase in diazepam 
use in health-care facilities in Yogyakarta between 2014 and 2016. 
Therefore, diazepam is needed in health-care facilities in Yogyakarta. 
However, diazepam was often unavailable in public health-care 
facilities. Yogyakarta is one of the Indonesian provinces which have the 
highest prevalence of mental disorders [13], hence the use of diazepam 
is needed more than other provinces. Diazepam is indicated for many 
treatments. The presence of 17 pharmaceutical industries in Indonesia 
which produce 42 branded and dosage forms showed that the demand 
for diazepam products is high.
Diazepam is used in almost every country. In the Republic of Macedonia, 
between 2003 and 2013, of all the patients requiring treatment 
with benzodiazepine, 59% were treated with 5 mg diazepam [14]. 
In Bosnia, diazepam was the most common psychotropic agent for 
outpatient uses between 2002 and 2008, followed by phenobarbital 
and carbamazepine [15]. In Latvia, between 2004 and 2007, diazepam 
was the most prescribed psychotropic (12 DDD/1000 people/day) 
compared to other psychotropic medicines such as bromazepam, 
alprazolam, oxazepam, nitrazepam, and clonazepam [16]. Data 
of outpatient prescriptions in general hospitals in Singapore 
between 2005 and 2013 showed high use of diazepam, alprazolam, 
and lorazepam [17]. The most common benzodiazepine used in 
outpatients from the Psychiatric Department in Academic Hospital 
in Karnataka, India, was clonazepam (47.86%), diazepam (21.05%), 
and lorazepam (18.95%) [18]. The most prescribed psychotropic in 
the Neurology Department of private hospital in Tamil Nadu, India, 
was phenytoin (92.10%), diazepam (36.84%), and sodium valproate 
(7.89%) [19]. Diazepam was the most commonly prescribed medicine 
for schizophrenia outpatients from the Psychiatric Department in the 
Owaisi Hospital and Research Center in Hyderabad, India (41.95%) 
and the least was aripiprazole (0.57%) [20]. Meanwhile, diazepam has 
the least frequency of potentially inappropriate medication use in the 
elderly population treated at Gondar University Hospital, Ethiopia [21]. 
Therefore, diazepam use should increase and not otherwise, as in 
Indonesia.
This study shows that one of the factors that affect diazepam use was 
limitation of availability. Frequent stockouts were reported, particularly 
of generic diazepam. Unavailability of diazepam caused obstacles 
in its use, especially in public health-care facilities, because public 
facilities mainly use the generic product. Although branded products 
were available, their use was low. Medicine use was influenced by four 
correlated factors: Health-care system, prescriber, dispenser, patients, 
and community [3]. From health-care system aspects, the obstacles 
were unreliable supplies, medicine shortage, expired medicine, 
and substandard, or fictitious products. Unreliable supplies clearly 
influenced use. Therefore, diazepam availability must be ensured by 
improving the supply system and increasing production to prevent 
stockouts.
Access to diazepam
Limitation of generic products availability leads to physicians 
prescribing branded products, although they are more costly than 
generic products. There were conspicuous price differences between 
generic diazepam products and branded ones. Data from Health 
Research and Development Agency of Indonesia in 2014 showed that 
there was a branded product of 5 mg diazepam which was 50 times 
more expensive compared to the generic product price [22].
Fig. 1: Consumption of diazepam and alprazolam in Indonesia 
during the 10‑year period of 2004‑2013
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Access to acquire essential medicine is influenced by price 
affordability [4], even though access to essential medicines is one of the 
human rights. Therefore, ensuring sustainable supply of diazepam is 
an obligation for the public and private health-care facilities [23]. For 
this reason, requantification of diazepam requirement is necessary to 
meet all domestic medical needs, and also to fulfill export demands. 
The estimation of diazepam requirements for domestic medical needs 
for various indications is ranging from 1 to 2 S-DDD, or approximately 
900-1800 kg per year. By simulation, to meet domestic medical 
demands of 1 S-DDD and export of 500 kg, up to 1580 kg of raw material 
will need to be imported. In reality, the highest quantity of diazepam 
import in Indonesia in 2013 was only 915 kg. Countries with the 
highest production of diazepam are Italy, China, Switzerland, UK, India, 
Germany, and Denmark [10].
McBain, [24] in a study about the role of health system factors in 63 low-
income countries and middle-to-low income countries in influencing 
accessibility to obtain psychotropics in health-care facilities found that 
the availability of psychotropics in 58 health-care facilities was 71%. The 
availability of psychotropics in low income and middle-to-low income 
countries was 70%, and in middle-to-high income countries was 82%. 
McBain also showed that the availability of psychotropics in a country 
was correlated with: (1) The presence of national laws, regulations, 
and policies about mental health which could increase psychotropics 
availability by 15%; (2) per capita income which had impact in 
budget allocation for mental health; (3) the presence of patient’s family 
participation which could determine mental health policy and increase 
the availability of psychotropics by 16.5%; and (4) the presence of 
mental health assessment and treatment standard in primary health-
care facilities, which could increase the availability of psychotropic by 
17%. Consequently, to increase the access for psychotropic treatment, 
including diazepam, several requirements such as price affordability, 
medicine availability, and an adequate mental health system would 
need to be fulfilled.
According to Barbui [25] access to psychotropic medicines in countries 
with limited ability could be improved through medicine availability 
regulation, implementation of reliable supply system (provision, 
supply, and distribution), quality control of psychotropic medicines, 
and implementation of community-based mental health system. 
Availability could be improved through development of stricter 
pricing policy and encouragement of continuous payment system with 
affordable medicine prices. Padmanathan suggested the presence of a 
budget allocation policy by the government, particularly for essential 
psychotropic medicines [26].
Diazepam versus alprazolam
Shortage of diazepam availability could increase utilization of other 
medicines with the same indication, such as alprazolam. Concurrently, 
there was an increase in alprazolam use since 2010. However, it 
is unclear whether there was a shift of usage from diazepam to 
alprazolam; alprazolam is not an essential medicine and is not used 
in public primary health-care facilities. It is likely that alprazolam use 
increased in private or referral health-care facilities. Alprazolam is 
used medically as an anxiolytic, while diazepam could be used as an 
anxiolytic, antiepileptic, muscle relaxant, and anesthetic premedication. 
Although alprazolam was used to fulfill the shortage of diazepam as an 
anxiolytic, it could not replace diazepam for other indications.
Diazepam is a long-acting benzodiazepine. It has a half-life of 20-80 hrs, 
whereas alprazolam has a half-life of 12-15 hrs [6]. Therefore, the 
hangover effect of diazepam is longer. Ambarsari [27] conducted a study 
in 437 patients who were prescribed benzodiazepine in a pharmacy in 
Yogyakarta, Indonesia in 2016. The study showed that alprazolam was 
prescribed in 87.18% of all benzodiazepine prescriptions, whereas 
diazepam was only 0.91%. Increase in alprazolam prescriptions 
was also reported in Australia [28]. Apparently, this phenomenon 
of increasing alprazolam use was not correlated with diazepam in 
availability.
Some studies indicated that there was an increase in the use of 
benzodiazepine-related medicines, such as zopiclone, zolpidem, 
zaleplon, and eszopiclone. This group is commonly known as Z-drugs. 
They have a short-acting effect at the benzodiazepine receptor [6]. 
It was estimated that almost 95% of Danish Z-drugs users use it for 
4 weeks, and more than 50% use it for 6 months [29]. The trend of 
zolpidem and zopiclone use in Denmark between 1997 and 2008 
was increasing while benzodiazepine was decreasing [30]. In Canada, 
there was a change in benzodiazepine prescription practice, especially 
for the elderly patients. Benzodiazepine prescription was decreasing 
while Z-drugs use was increasing. Similar trends were also found in 
other international studies [31]. Z-drugs in branded dosage form are 
available in Indonesia, but the extent of its use in relation to diazepam 
is not known.
This study showed that the decrease in diazepam usage is correlated 
with an unreliable supply system. It will need improvements in 
production and supply system, to prevent a shortage of medicines. 
To prevent the shortage of essential medicines, requantification of 
domestic medical needs is needed. Inaccurate quantification will 
obviously result in an incorrect calculation of medical requirements, 
thereby limiting the amount of controlled substances available to the 
country [32].
CONCLUSION
Consumption and use of diazepam as an essential medicine were 
decreasing for the last 10 years. Diazepam availability was not 
maintained; as a result, there were numerous shortages in health-care 
facilities. Supply systems are important factors that determine the 
availability of medicine, which would affect health care quality. The 
government should meet the needs of diazepam by improving factors 
that affect its use, such as requantifying diazepam needs and ensuring 
its appropriate production and distribution.
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